WO1997008205B1 - Anticorps presentant deux specificites ou plus pour l'elimination specifique de cellules in vivo - Google Patents
Anticorps presentant deux specificites ou plus pour l'elimination specifique de cellules in vivoInfo
- Publication number
- WO1997008205B1 WO1997008205B1 PCT/EP1996/003734 EP9603734W WO9708205B1 WO 1997008205 B1 WO1997008205 B1 WO 1997008205B1 EP 9603734 W EP9603734 W EP 9603734W WO 9708205 B1 WO9708205 B1 WO 9708205B1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibody
- antigen
- tumor
- antigens
- cell
- Prior art date
Links
- 238000001727 in vivo Methods 0.000 title claims abstract 3
- 230000008030 elimination Effects 0.000 title 1
- 238000003379 elimination reaction Methods 0.000 title 1
- 108091007433 antigens Proteins 0.000 claims abstract 28
- 102000036639 antigens Human genes 0.000 claims abstract 28
- 239000000427 antigen Substances 0.000 claims abstract 27
- 210000004881 tumor cell Anatomy 0.000 claims abstract 9
- 239000003814 drug Substances 0.000 claims abstract 4
- 239000000203 mixture Substances 0.000 claims abstract 2
- 210000004027 cell Anatomy 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 239000012636 effector Substances 0.000 claims 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims 2
- 238000009169 immunotherapy Methods 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 230000003211 malignant effect Effects 0.000 claims 2
- 102100022749 Aminopeptidase N Human genes 0.000 claims 1
- 208000003950 B-cell lymphoma Diseases 0.000 claims 1
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 1
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims 1
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 claims 1
- 101150013553 CD40 gene Proteins 0.000 claims 1
- 108010058905 CD44v6 antigen Proteins 0.000 claims 1
- 241000189662 Calla Species 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 102100032768 Complement receptor type 2 Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 101710190709 Eukaryotic translation initiation factor 4 gamma 2 Proteins 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 claims 1
- 101000757160 Homo sapiens Aminopeptidase N Proteins 0.000 claims 1
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 1
- 101000941929 Homo sapiens Complement receptor type 2 Proteins 0.000 claims 1
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 claims 1
- 101001078143 Homo sapiens Integrin alpha-IIb Proteins 0.000 claims 1
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 claims 1
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 claims 1
- 101000917826 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-a Proteins 0.000 claims 1
- 101000917824 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-b Proteins 0.000 claims 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 claims 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims 1
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 claims 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 1
- 101000835093 Homo sapiens Transferrin receptor protein 1 Proteins 0.000 claims 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims 1
- 108010043496 Immunoglobulin Idiotypes Proteins 0.000 claims 1
- 102100025306 Integrin alpha-IIb Human genes 0.000 claims 1
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 claims 1
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 claims 1
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 claims 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 claims 1
- 101000686985 Mouse mammary tumor virus (strain C3H) Protein PR73 Proteins 0.000 claims 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims 1
- 102000003729 Neprilysin Human genes 0.000 claims 1
- 108090000028 Neprilysin Proteins 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 102100038081 Signal transducer CD24 Human genes 0.000 claims 1
- 206010042971 T-cell lymphoma Diseases 0.000 claims 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 1
- 102100026144 Transferrin receptor protein 1 Human genes 0.000 claims 1
- 101710132062 Transitional endoplasmic reticulum ATPase Proteins 0.000 claims 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims 1
- 229960002685 biotin Drugs 0.000 claims 1
- 235000020958 biotin Nutrition 0.000 claims 1
- 239000011616 biotin Substances 0.000 claims 1
- 201000008275 breast carcinoma Diseases 0.000 claims 1
- -1 c-erb-B2 Proteins 0.000 claims 1
- 201000010989 colorectal carcinoma Diseases 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 150000002270 gangliosides Chemical class 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 208000029824 high grade glioma Diseases 0.000 claims 1
- 201000011614 malignant glioma Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 231100000617 superantigen Toxicity 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 238000000338 in vitro Methods 0.000 abstract 1
Abstract
L'invention concerne des anticorps présentant deux spécificités ou plus, identifiant deux différents antigènes situés sur une cellule tumorale, ainsi que des médicaments et des compositions diagnostiques contenant lesdits anticorps. Les anticorps et les médicaments décrits s'utilisent notamment pour l'identification et l'élimination spécifiques de cellules tumorales in vivo ou in vitro.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19531348.8 | 1995-08-25 | ||
| DE1995131348 DE19531348A1 (de) | 1995-08-25 | 1995-08-25 | Antikörper mit zwei oder mehr Spezifitäten zur selektiven Eliminierung von Zellen in vivo |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO1997008205A1 WO1997008205A1 (fr) | 1997-03-06 |
| WO1997008205B1 true WO1997008205B1 (fr) | 1997-05-15 |
Family
ID=7770410
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP1996/003734 WO1997008205A1 (fr) | 1995-08-25 | 1996-08-23 | Anticorps presentant deux specificites ou plus pour l'elimination specifique de cellules in vivo |
Country Status (2)
| Country | Link |
|---|---|
| DE (1) | DE19531348A1 (fr) |
| WO (1) | WO1997008205A1 (fr) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2753368B1 (fr) | 1996-09-13 | 1999-01-08 | Chauvin Jean Luc | Cage d'osteosynthese expansive |
| BRPI9909860B8 (pt) | 1998-04-21 | 2021-05-25 | Amgen Res Munich Gmbh | polipeptídeo multifuncional de cadeia simples, polinucleotídeo, vetor, célula procariótica, de levedura ou unicelular, composição, usos de polipeptídeo e polinucleotídeo e métodos para preparo do referido polipeptídeo e para identificação de ativadores ou inibidores de ativação ou estimulação das células t |
| DE10034607A1 (de) | 2000-07-20 | 2002-02-07 | Gundram Jung | Multispezifisches Reagenz zur selektiven Stimulierung von Zelloberflächenrezeptoren |
| DE10043437A1 (de) | 2000-09-04 | 2002-03-28 | Horst Lindhofer | Verwendung von trifunktionellen bispezifischen und trispezifischen Antikörpern zur Behandlung von malignem Aszites |
| AT413486B (de) * | 2002-07-03 | 2006-03-15 | Igeneon Krebs Immuntherapie | Verwendung eines antikörpers gerichtet gegen lewis-antigene |
| AT500648B1 (de) | 2002-08-12 | 2010-03-15 | Igeneon Krebs Immuntherapie | Set zur behandlung von krebspatienten |
| RU2005137325A (ru) | 2003-05-31 | 2006-09-10 | Микромет Аг (De) | Фармацевтическая композиция, содержащая конструкт, специфичный к ерсам |
| US7635472B2 (en) | 2003-05-31 | 2009-12-22 | Micromet Ag | Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders |
| JP6263314B2 (ja) | 2014-06-04 | 2018-01-17 | ヴェンツェル スパイン，インコーポレイテッド | バイラテラルに拡張する椎体間固定装置 |
| BR112019016248A2 (pt) | 2017-02-07 | 2020-04-14 | Oblique Therapeutics Ab | piridinas substituídas com hidrocarbilssulfonila e uso das mesmas no tratamento de câncer |
| US11219531B2 (en) | 2019-04-10 | 2022-01-11 | Wenzel Spine, Inc. | Rotatable intervertebral spacing implant |
| JP7489407B2 (ja) | 2019-05-21 | 2024-05-23 | ノバルティス アーゲー | Ｃｄ１９結合分子及びその使用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4978745A (en) * | 1987-11-23 | 1990-12-18 | Centocor, Inc. | Immunoreactive heterochain antibodies |
| AU6290090A (en) * | 1989-08-29 | 1991-04-08 | University Of Southampton | Bi-or trispecific (fab)3 or (fab)4 conjugates |
| ZA914625B (en) * | 1990-06-22 | 1993-02-24 | Lilly Co Eli | In vivo targeting with bifunctional antibodies |
| DE4028955A1 (de) * | 1990-09-12 | 1992-03-19 | Boehringer Mannheim Gmbh | Monoklonale antikoerper gegen den interleukin 2-rezeptor |
| FR2672291A1 (fr) * | 1991-01-31 | 1992-08-07 | Inst Nat Sante Rech Med | Composition d'anticorps diriges contre le recepteur de l'interleukine-2 humaine ou animale. |
| EP0596011A1 (fr) * | 1991-07-19 | 1994-05-11 | Hybritech Incorporated | Composes trifonctionnels presentant une specificite contre les cellules resistant a plusieurs medicaments-------------------- |
| AU7241094A (en) * | 1993-04-09 | 1994-11-08 | Chiron Corporation | Bispecific antigen-binding molecules |
-
1995
- 1995-08-25 DE DE1995131348 patent/DE19531348A1/de not_active Withdrawn
-
1996
- 1996-08-23 WO PCT/EP1996/003734 patent/WO1997008205A1/fr active Application Filing
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO1997008205B1 (fr) | Anticorps presentant deux specificites ou plus pour l'elimination specifique de cellules in vivo | |
| US4978745A (en) | Immunoreactive heterochain antibodies | |
| Weiner et al. | Phase I trial of 2B1, a bispecific monoclonal antibody targeting c-erbB-2 and FcγRIII | |
| AU761387B2 (en) | Bispecific antibodies for retargeting anticancer cytotoxic lymphocytes and hybriomas and monoclonal antibodies therefore | |
| AU605771B2 (en) | Monoclanal antibodies to Fc receptors for immunoglobulin G on human mononuclear phagocytes | |
| Hombach et al. | A chimeric receptor that selectively targets membrane-bound carcinoembryonic antigen (mCEA) in the presence of soluble CEA | |
| MY108519A (en) | Novel antibodies reactive with human carcinomas. | |
| Hombach et al. | A CD16/CD30 bispecific monoclonal antibody induces lysis of hodgkin's cells by unstimulated natural killer cells In AND In vivo | |
| Heuser et al. | T-cell activation by recombinant immunoreceptors: impact of the intracellular signalling domain on the stability of receptor expression and antigen-specific activation of grafted T cells | |
| WO1997007819B1 (fr) | Medicaments s'utilisant en immunotherapie et contenant des anticorps identifiant specifiquement l'antigene du mhcii d'un patient a traiter | |
| EP0256654A3 (fr) | Immunoglobuline chimère murine-humaine, spécifique pour l' antigène 17-1A associés aux tumeurs | |
| EP0369566A2 (fr) | Anticorps chimériques bifonctionnels | |
| DE69033181T2 (de) | Iga-rezeptorspezifische monoklonale antikörper | |
| Lloyd | Human tumor antigens: detection and characterization with monoclonal antibodies | |
| EP0845998A1 (fr) | Medicaments s'utilisant en immunotherapie et contenant des anticorps identifiant specifiquement l'antigene du mhcii d'un patient a traiter | |
| Carroll et al. | Idiotype variant cell populations in patients with B cell lymphoma. | |
| Michon et al. | In vitro killing of neuroblastoma cells by neutrophils derived from granulocyte colony-stimulating factor-treated cancer patients using an anti-disialoganglioside/anti-Fc gamma RI bispecific antibody | |
| HUP9901597A2 (hu) | Eljárás nemkívánt célsejtek elpusztítására | |
| Hellström et al. | Antibody-mediated killing of human tumor cells by attached effector cells | |
| WO1997008205A1 (fr) | Anticorps presentant deux specificites ou plus pour l'elimination specifique de cellules in vivo | |
| Van Ojik et al. | Clinical evaluation of the bispecific antibody MDX-H210 (anti-FcγRI× anti-HER-2/neu) in combination with granulocyte-colony-stimulating factor (Filgrastim) for treatment of advanced breast cancer | |
| Corvalan et al. | Classification of anti-CEA monoclonal antibodies | |
| de Gast et al. | Clinical perspectives of bispecific antibodies in cancer | |
| Liao et al. | Immunohistochemical phenotyping of human solid tumors with monoclonal antibodies in devising biotherapeutic strategies | |
| MASUCCI et al. | Effect of Human Blood Mononuclear Cell Populations in Antibody Dependent Cellular Cytotoxicity (ADCC) Using Two Murine (CO 17-1A and Br55-2) and One Chimeric (17-1A) Monoclonal Antibodies Against a Human Colorectal Carcinoma Cell Line (SW948) |